Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
about
Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa RicaEstimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccinationAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerPreventive vaccination against cervical cancer: Korean Society of Gynecologic Oncology GuidelineHuman papillomavirus-associated cancers: a survey on otorhinolaryngologists' knowledge and attitudes on preventionClinical significance of human papillomavirus genotypingAre the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPVAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.VIN usual type-from the past to the futureLessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteinsAACR Cancer Progress Report 2014Long-term efficacy and safety of human papillomavirus vaccinationEarly direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic reviewThe combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinomaEvaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort StudySocial Networks Influence Hispanic College Women's HPV Vaccine Uptake Decision-making ProcessesEurogin Roadmap 2015: How has HPV knowledge changed our practice: Vaccines.Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa RicaModeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.Potential anti-HPV and related cancer agents from marine resources: an overview.Variation in Human Papillomavirus Vaccine Uptake and Acceptability Between Female and Male Adolescents and Their Caregivers.Highlights from the first ecancer-Liga Colombiana contra el Cancer conference, 17-18 November 2016, Bogota, Colombia.Deciphering the Multifactorial Susceptibility of Mucosal Junction Cells to HPV Infection and Related Carcinogenesis.Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialA multicountry evaluation of careHPV testing, visual inspection with acetic acid, and papanicolaou testing for the detection of cervical cancer.Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.Modeling optimal cervical cancer prevention strategies in Nigeria.Prospects for prevention of HPV-driven oropharynx cancer.Improving Human Papillomavirus (HPV) Vaccination in the Postpartum Setting.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPVIn vivo mechanisms of vaccine-induced protection against HPV infection.Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.HPV catch-up vaccination of young women: a systematic review and meta-analysis.Perspective for prophylaxis and treatment of cervical cancer: an immunological approach.Immunological treatment options for locoregionally advanced head and neck squamous cell carcinomaEfficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policiesEffect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
P2860
Q21089767-FF0CF870-8371-4E13-A771-40B8E9C968A4Q21261267-FB6B2721-59BD-4198-A2D0-9F0E73E89BAFQ24607403-BE8BF226-38A5-41DA-8991-290E9FB8E842Q26749285-12A900C3-D1AA-4DA9-AA07-FD4D86CAAAA5Q26768614-9AAE4977-3630-4B29-8834-E799AD087C26Q26771981-FEBD4F3D-AA3C-4D0B-A3D3-4920778814B1Q26783973-21EBC1B2-5FAF-4C70-9974-FCE84E86BAC7Q26828840-31CF079C-AB9C-4C45-AFAC-824F96DE5E2AQ26865303-22DFB501-F479-4950-974A-41AD9DBD2F2CQ27013018-64173E12-ECB4-4EFC-9AC4-7A1D5350C3FBQ27346723-30C73719-3FEA-47E3-8260-8F4D211014F8Q28081156-FA28A14A-C50E-42DE-9F23-EFAC95668267Q28081927-0EEF1315-E9F8-41AC-9EB3-2700C37EA55EQ28387851-DBCCD5AF-F666-4F3F-BFB8-1E56BFBE9C5DQ28647510-13B18482-F5A8-44E0-998D-87D14CFD9C31Q28652207-33B99019-74E3-478A-8C29-A9D186CC440DQ30251868-C615C9F7-6917-410A-B5F4-9B6604FDE00EQ30300329-A88629C4-F7CC-4F04-AC16-992AB6E74A4AQ30573204-C8570812-71D0-43AE-94F0-1F0F65B89461Q30682187-F540E448-516C-45C0-B7B5-43189EEE6D28Q33575647-B8FAC4D2-D95C-4052-BCFD-26E914288755Q33599209-185A704A-EE0D-42C5-B0C6-7909614DD514Q33606735-4DBA4444-38C9-44BB-9E79-EDEE1BC677A7Q33613540-119BFCEF-64CA-4EDA-B944-C7FA7CCF8C81Q33626255-012051B8-049C-4483-AC5F-4B0AB7377966Q33718190-FF260F17-A7FD-468A-9027-53A6CB2F7ADCQ33724422-FF553DA5-5161-4360-9CE7-3358BBED695AQ33755002-44E0E41C-C3F7-4CC2-BB9E-4C34E839B163Q33759930-52145133-1A2B-4EC7-BE9B-1E29BC053A8AQ33905003-FBA05189-8C50-4447-B00F-52BD88BA12AAQ33953881-3EBC6693-4257-4376-849A-00FF4953C79FQ33963857-CA491156-A913-4A9B-8386-7B802751B626Q34125906-BFE138AD-27A6-41E7-A7DD-3CC409A1FF5CQ34149348-02B03C99-07AE-4729-AEDF-CEF7A0BDE9F2Q34157209-29DFB153-2D26-49EF-A7A9-93FDAE9DB870Q34181909-5C840C60-FCD0-4E76-A5CE-557F12430A64Q34181954-B1431579-310A-4D21-8DCE-B89287399D31Q34199560-5B82FD32-4C02-4E25-A5E7-77BF1C9F646AQ34199773-5B5B8C44-47E9-4566-BC00-871FB306364CQ34210255-64BE88D3-5599-413C-A64F-D31BEEC8BDA0
P2860
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Impact of human papillomavirus ...... nital diseases in young women.
@en
Impact of human papillomavirus
@nl
type
label
Impact of human papillomavirus ...... nital diseases in young women.
@en
Impact of human papillomavirus
@nl
prefLabel
Impact of human papillomavirus ...... nital diseases in young women.
@en
Impact of human papillomavirus
@nl
P2093
P2860
P50
P356
P1476
Impact of human papillomavirus ...... nital diseases in young women.
@en
P2093
Amha Tadesse
Daron G Ferris
Darron R Brown
Eliav Barr
Elmar A Joura
Eng Hseon Tay
Evan R Myers
F Xavier Bosch
Frank J Taddeo
Gonzalo Perez
P2860
P304
P356
10.1093/JNCI/DJP534
P407
P577
2010-02-05T00:00:00Z